Influx Healthtech IPO
Influx Healthtech IPO
Influx Healthtech Ltd
₹1,09,200 / 1200 Shares
Minimum Investment
Influx Healthtech IPO Details
Open Date
18 Jun 2025
Close Date
20 Jun 2025
Lot Size
1200
Min. Investment
₹1,09,200
About Influx Healthtech
Influx Healthtech Limited is a Mumbai-based healthcare company that is in the contract manufacturing space. Established in 2020, it operates as a contract development and manufacturing organisation (CDMO), providing services across various industries. The company’s product offerings include dietary and nutritional supplements, cosmetics, Ayurvedic and herbal formulations, veterinary feed supplements, and homecare products. These are available in multiple forms, including tablets, capsules, powders, liquids, softgels, and creams. Influx Healthtech operates manufacturing facilities in Thane, Maharashtra. The facilities are certified to international quality standards, including Good Manufacturing Practice (GMP), Hazard Analysis and Critical Control Points (HACCP), and Halal.
Founded In
2020
Managing Director
Mr Munir Abdul Ganee Chandniwala
Parent Organization
Influx Healthtech Ltd
Application Details of Influx Healthtech IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Regular | ₹91 - ₹96 | ₹2 Lakh |
| High Networth Individual | ₹91 - ₹96 | ₹2 - 5 Lakh |
Open On12 Dec 2025
Close On16 Dec 2025
Price Range₹2061-2165
Testimonial
Genuine Review Form Statisifed Customers
I appreciated how KSquare simplified the NPS jargon. Everything was laid out clearly with ongoing support.
I was impressed by how seamless KSquare’s NRI services are. They handled my documentation with care and helped me invest without unnecessary hassle.
KSquare delivers excellent service and fund recommendations. The platform makes investing feel less like a chore and more like a plan I’m excited to follow.
Thanks to KSquare, I managed urgent expenses without disturbing my mutual funds. Really smooth experience overall.
I needed urgent cash flow and didn’t want to redeem my funds. KSquare had the perfect solution. Very helpful service!
KSquare’s New Fund Offering system is reliable and easy to follow. Their pre-launch alerts and fund guides helped me confidently choose what’s best for me.
KSquare’s service was fast, transparent, and easy to follow. Perfect for someone like me who needed quick access to funds.
KSquare made the loan process so efficient that I didn’t feel stressed at all. Fantastic customer support as well.
KSquare’s team explained everything clearly. I never thought borrowing against my mutual funds would be this easy.
Thanks to KSquare, I purchased my first car without loans. The SIP plan was perfectly calculated and aligned with my budget, making everything financially smooth and stress-free.
FAQ's
Frequenlty Asked Question
What happens if I stop my SIP before maturity?
You can withdraw your invested amount anytime. However, early exits might impact your long-term growth potential.
How are mutual fund returns calculated?
Returns are based on the Net Asset Value (NAV) movement of the fund and any dividends paid out over time.
Are mutual funds safe to invest in?
Mutual funds carry market risk, but diversification and professional management help reduce volatility and improve long-term growth potential.
How does KSquare ensure compliance with FEMA rules?
KSquare’s advisory follows all FEMA guidelines, helping NRIs invest safely while staying compliant with Indian regulations.
Can NRIs invest in mutual funds through KSquare?
Yes, NRIs can easily invest in SEBI-registered mutual funds via KSquare using NRE or NRO bank accounts.
Can I invest in SIPs from abroad with KSquare?
Yes, NRIs can set up SIPs through their NRE/NRO accounts. KSquare automates the process for convenience.
How do I track my investments from overseas?
KSquare’s online dashboard lets NRIs monitor and manage portfolios 24/7, no matter where they are in the world.
How is SIP different from recurring deposits?
Unlike fixed-interest recurring deposits, SIP returns are market-linked and offer higher growth potential with some risk.